Irit Gliko-Kabir
Chief Tech/Sci/R&D Officer at BIOLINERX LTD.
Profile
Irit Gliko-Kabir is currently working as the Vice President-Clinical Operations at BioLineRx Ltd.
She started this position in 2021.
Previously, she worked as the Senior Director-Clinical Development at Bioblast Pharma Ltd.
Dr. Gliko-Kabir has an educational background, having obtained undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Irit Gliko-Kabir active positions
Companies | Position | Start |
---|---|---|
BIOLINERX LTD. | Chief Tech/Sci/R&D Officer | 2017-08-31 |
Former positions of Irit Gliko-Kabir
Companies | Position | End |
---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Chief Tech/Sci/R&D Officer | - |
Training of Irit Gliko-Kabir
The Hebrew University of Jerusalem | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Private companies | 1 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Stock Market
- Insiders
- Irit Gliko-Kabir